Ｖｅｒｉｔａｓ Ｉｎ Ｓｉｌｉｃｏの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/06/10 | 1,054 | 1,115 | 1,053 | 1,099 | +34 | +3.2% | 22,600 |
| 2024/06/07 | 1,141 | 1,141 | 1,039 | 1,065 | -77 | -6.7% | 38,600 |
| 2024/06/06 | 1,188 | 1,199 | 1,111 | 1,142 | -42 | -3.5% | 23,800 |
| 2024/06/05 | 1,152 | 1,219 | 1,152 | 1,184 | +25 | +2.2% | 24,200 |
| 2024/06/04 | 1,125 | 1,183 | 1,125 | 1,159 | +49 | +4.4% | 21,400 |
| 2024/06/03 | 1,154 | 1,154 | 1,107 | 1,110 | -42 | -3.6% | 14,300 |
| 2024/05/31 | 1,108 | 1,152 | 1,097 | 1,152 | +44 | +4% | 13,900 |
| 2024/05/30 | 1,150 | 1,150 | 1,088 | 1,108 | -53 | -4.6% | 37,300 |
| 2024/05/29 | 1,174 | 1,211 | 1,130 | 1,161 | -1 | -0.1% | 33,400 |
| 2024/05/28 | 1,080 | 1,235 | 1,074 | 1,162 | +74 | +6.8% | 76,700 |
| 2024/05/27 | 1,050 | 1,102 | 1,046 | 1,088 | +51 | +4.9% | 23,500 |
| 2024/05/24 | 1,050 | 1,067 | 1,024 | 1,037 | -13 | -1.2% | 28,000 |
| 2024/05/23 | 1,072 | 1,082 | 1,042 | 1,050 | -20 | -1.9% | 33,500 |
| 2024/05/22 | 1,143 | 1,143 | 1,070 | 1,070 | -61 | -5.4% | 40,100 |
| 2024/05/21 | 1,119 | 1,145 | 1,095 | 1,131 | +18 | +1.6% | 38,900 |
| 2024/05/20 | 1,069 | 1,139 | 1,062 | 1,113 | +33 | +3.1% | 40,400 |
| 2024/05/17 | 1,113 | 1,115 | 1,072 | 1,080 | -30 | -2.7% | 73,100 |
| 2024/05/16 | 1,130 | 1,160 | 1,090 | 1,110 | -20 | -1.8% | 58,000 |
| 2024/05/15 | 1,200 | 1,220 | 1,123 | 1,130 | -64 | -5.4% | 88,900 |
| 2024/05/14 | 1,186 | 1,238 | 1,186 | 1,194 | +9 | +0.8% | 52,600 |
| 2024/05/13 | 1,185 | 1,213 | 1,139 | 1,185 | ±0 | ±0% | 124,500 |
| 2024/05/10 | 1,381 | 1,383 | 1,178 | 1,185 | -218 | -15.5% | 192,400 |
| 2024/05/09 | 1,465 | 1,470 | 1,401 | 1,403 | -92 | -6.2% | 86,900 |
| 2024/05/08 | 1,580 | 1,581 | 1,470 | 1,495 | -135 | -8.3% | 197,400 |
| 2024/05/07 | 1,910 | 1,929 | 1,578 | 1,630 | -240 | -12.8% | 167,100 |
| 2024/05/02 | 1,817 | 1,897 | 1,800 | 1,870 | +55 | +3% | 59,600 |
| 2024/05/01 | 1,691 | 1,840 | 1,691 | 1,815 | +84 | +4.9% | 60,100 |
| 2024/04/30 | 1,670 | 1,813 | 1,600 | 1,731 | +54 | +3.2% | 59,300 |
| 2024/04/26 | 1,635 | 1,700 | 1,595 | 1,677 | +42 | +2.6% | 24,400 |
| 2024/04/25 | 1,650 | 1,650 | 1,581 | 1,635 | -17 | -1% | 16,200 |
| 2024/04/24 | 1,677 | 1,692 | 1,652 | 1,652 | -41 | -2.4% | 13,600 |
| 2024/04/23 | 1,670 | 1,716 | 1,635 | 1,693 | +23 | +1.4% | 12,500 |
| 2024/04/22 | 1,625 | 1,670 | 1,585 | 1,670 | +50 | +3.1% | 15,300 |
| 2024/04/19 | 1,652 | 1,666 | 1,600 | 1,620 | -49 | -2.9% | 35,800 |
| 2024/04/18 | 1,650 | 1,686 | 1,620 | 1,669 | +19 | +1.2% | 18,200 |
| 2024/04/17 | 1,701 | 1,730 | 1,650 | 1,650 | -59 | -3.5% | 36,100 |
| 2024/04/16 | 1,746 | 1,789 | 1,688 | 1,709 | -37 | -2.1% | 30,500 |
| 2024/04/15 | 1,660 | 1,750 | 1,657 | 1,746 | +46 | +2.7% | 28,700 |
| 2024/04/12 | 1,791 | 1,825 | 1,700 | 1,700 | -91 | -5.1% | 30,800 |
| 2024/04/11 | 1,847 | 1,847 | 1,770 | 1,791 | -29 | -1.6% | 23,700 |
| 2024/04/10 | 1,750 | 1,820 | 1,690 | 1,820 | +70 | +4% | 54,700 |
| 2024/04/09 | 1,814 | 1,878 | 1,744 | 1,750 | -87 | -4.7% | 57,700 |
| 2024/04/08 | 1,850 | 2,000 | 1,825 | 1,837 | +64 | +3.6% | 106,400 |
| 2024/04/05 | 1,670 | 1,814 | 1,640 | 1,773 | +92 | +5.5% | 120,700 |
| 2024/04/04 | 1,820 | 1,864 | 1,681 | 1,681 | -138 | -7.6% | 110,200 |
| 2024/04/03 | 1,930 | 1,954 | 1,819 | 1,819 | -142 | -7.2% | 91,400 |
| 2024/04/02 | 2,161 | 2,259 | 1,941 | 1,961 | -173 | -8.1% | 247,400 |
| 2024/04/01 | 2,023 | 2,330 | 2,023 | 2,134 | +151 | +7.6% | 436,300 |
| 2024/03/29 | 1,851 | 2,200 | 1,835 | 1,983 | +160 | +8.8% | 356,800 |
| 2024/03/28 | 1,891 | 1,900 | 1,809 | 1,823 | -87 | -4.6% | 71,500 |
201～
250
件表示中 / 282件
類似銘柄と比較する
現在ご覧いただいている「ＶＩＳ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＶＩＳ | 69,100円 | +306.2% | - | 0.00% | 26.68倍 | 2.03倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| キッズバイオ | 10,900円 | - | - | 0.00% | - | 6.06倍 |
|
北大発創薬ベンチャー。バイオ後続品を主力に、乳歯歯髄幹細胞（ＳＨＥＤ）用いた再生医療に力 |
| ＤＷＴＩ | 10,200円 | -15.1% | - | 0.00% | - | 6.31倍 |
|
三重大学発創薬ベンチャー。プロテインキナーゼ阻害剤開発技術はじめ眼病治療薬開発に集中 |
| 免疫生物 | 42,800円 | +13.4% | +44.0% | 0.00% | 18.54倍 | 2.98倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
| リボミック | 8,700円 | - | - | 0.00% | - | 1.18倍 |
|
東大発の創薬ベンチャー。ＲＮＡ（リボ核酸）を利用した分子標的薬（アプタマー医薬）を開発 |
市場注目の銘柄
チャート関連のコラム
